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Parenteral solutions (PS) are one of the most commonly used drug delivery vehicles. Interactions among 
the drug, components in the drug’s formulation, and the PS can result in the formation of inactive 
complexes that limit efficacy or increase side effects. The aim of this work was to evaluate possible 
interactions between the drugs and PS, assess drug stability and to identify degradation products after 
20 h at room temperature. Furosemide (FSM) and Aminophylline (APN) were added to PS containing 
either 20% mannitol or 0.9% NaCl at pH 6.5-7.5 and 10-11. Their behavior was studied individually 
and as an admixture, after 1 h oxidation with H2O2, using a spectrophotometer and HPLC. Individually, 
FSM and APN added to 20% mannitol and 0.9% NaCl solutions had the highest stability at pH 10-11. 
When FSM and APN were combined, the behavior of FSM was similar to the behavior observed for the 
drug individually in the same solutions. With the drugs combined in 20% mannitol pH 10-11, HPLC 
showed that both drugs were stable after a 20 h period yielding two distinct peaks; in oxidized samples, 
the elution profile showed four peaks with retention times unrelated to the untreated samples.
Uniterms: Parenteral solutions. Spectrophotometer. High Performance Liquid Chromatography. 
Furosemide. Aminophylline.
Soluções parenterais de grande volume são frequentemente utilizadas no ambiente hospitalar para a 
veiculação de fármacos. No entanto, possíveis incompatibilidades entre as estruturas dos fármacos, 
em diferentes veículos de administração, podem gerar possíveis associações antagônicas ou sinérgicas, 
resultando em alterações das propriedades físico-químicas, consequentemente, dos efeitos farmacológicos 
e das respostas clínicas esperadas. Este artigo avaliou a estabilidade e a possível formação de produtos 
de degradação entre os fármacos furosemida e aminofilina quando estes foram veiculados em soluções 
parenterais, após o preparo e após o período de 20 h. Furosemida e aminofilina foram adicionadas às 
soluções de 20% manitol e 0,9% NaCl nos valores de pH 6,5-7,5 e 10-11. A estabilidade dos fármacos 
foi avaliada individualmente, combinada e após degradação com peróxido de hidrogênio através de 
espectrofotometria de UV e HPLC. Furosemida e aminofilina individualmente avaliadas mostraram 
alta estabilidade em ambas as soluções estudadas nos valores de pH 10-11. Quando os fármacos foram 
combinados o comportamento da furosemida foi similar ao observado na ausência de aminofilina. Os 
fármacos combinados em 20% manitol pH10-11 por HPLC foram estáveis após o período de 20 h. Após 
degradação o perfil de cromatograma encontrado foi diferente do observado na ausência de degradação 
mostrando que o método é indicativo de estabilidade.
Uniterms: Soluções parenterais. Espectrofotometria. Cromatografia líquida de alta eficiência. Furosemida. 
Aminofilina.
INTRODUCTION
Parenteral solutions (PS) are one of the most com-
monly used drug delivery vehicles. The investigation of 
drug stability in parenteral solutions and their formula-
tions is important in the administration and efficacy of any 
treatment. Interactions among drugs, components in the 
drug’s formulation, and parenteral solutions can result in 
the formation of inactive complexes that limit efficacy or 
increase side effects.
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The addition of drugs to parenteral solutions, either 
individually or combined, alters the physical and chemical 
properties of these solutions. The key parameters are changes 
in pH, in ion concentrations and the addition of solvents.
Furosemide (FSM) is a potent diuretic widely used 
in the treatment of edema associated with heart and renal 
disorders (Katzung et al., 1998). Furosemide primarily 
inhibits sodium and chloride reabsorption in the thick 
ascending limb of the loop of Henle (Florence, Attwood, 
2003) promoting increased elimination of potassium, 
magnesium, calcium and, to a lesser extent, bicarbonates 
(Florence, Attwood, 2003; Goodman et al., 2005).
Furosemide is an acidic (pKa = 3.9), white to 
slightly yellowish solid commercially available diluted 
in basic solutions, using NaOH to increase its water 
solubility (Thomas, Altman, 1987). It is unstable at acidic 
pH (Martindale, 1993) undergoing hydrolysis and pho-
todegradation (Hitoshi et al., 1995) into furfuryl alcohol 
and 4-chloro-5-sulfamoylanthranilic acid; the furfuryl 
alcohol decomposes further to levulinic acid and other 
decomposition products, as elucidated by Kovar et al. 
(1974).
The stability of furosemide in water and aque-
ous solutions, composed of NaOH, HCl, (NH4)2HPO4, 
phosphate buffers, sorbitol and other components, were 
examined at temperatures from 24 oC to 85 oC over 7 to 
182 days by Ghanekar et al. (1978). Their results showed 
that furosemide stability was related to pH and tempera-
ture of the solutions proving unstable in acidic media and 
very stable in basic media. The addition of alcohol to 50% 
sorbitol solutions at pH 8.5 stabilized furosemide for up 
to 182 days at 24 oC.
Kirit et al. (1980) studied the effects of pH, chloro-
butanol, cysteine HCl, EDTA, propylene glycol, sodium 
metabisulfite and sodium sulfite in aqueous solutions 
(25 oC), on furosemide stability. These authors reiterated 
that the critical parameter in furosemide stability was pH, 
with the highest stability at basic pH throughout the shelf 
life of aqueous solutions of furosemide.
As an admixture, furosemide was shown to be com-
patible with ceftazidime in parenteral nutrient solution 
for 24 h (25 oC) (Servais, Tulkens, 2001) and stable in a 
solution of 25% human albumin for 48 h at 25 oC and 14 d 
at 4 oC (Elwell et al., 2002).
Theophylline, a naturally occurring methylxanthi-
ne derivative, competitively inhibits phosphodiesterase, 
resulting in increasing amounts of cyclic AMP (cAMP) 
which promotes the release of endogenous epinephrine. 
Increased levels of cAMP may also inhibit the release of 
histamine and of slow reacting substance of anaphy laxis 
(SRS-A) (Dawson et al., 1986).
Aminophylline, a 2:1 complex of theophylline and 
ethylenediamine, has two distinct actions: smooth mus-
cle relaxation (bronchodilation) and suppression of the 
response of the airways to stimuli (non-bronchodilator 
effects). It is generally administered by continuous intra-
venous infusion when used as a potent bronchodilator in 
the treatment of lung diseases (Korolkovas, 1988).
Aminophylline was shown to be stable in alkaline 
solutions (optimal pH 8.6-9.0) but dissociates into theo-
phylline and ethylenediammonium ions at pH 2.4-3.0. In 
the presence of CO2, aminophylline dissociates into theo-
phylline (Dawson et al., 1986) and upon exposure to light 
and oxygen decomposes into 1,3-dimethylallantoin, N,N’-
dimethyloxamide and ammonia (Ishiguro et al., 1991).
Aminophylline was shown to be stable for 24 h in 
parenteral nutrient solutions (PN) (25 oC) at concentrations 
≤1.5 mg/mL (16) and PN in DIMIX bags (Ciszewska-
Jedraski et al., 1995), and for 91 days in Ora Sweet:Ora 
Plus oral suspension with 3 mg/mL (4 oC and 25 oC) and 
21 mg/mL (25 oC) (Chong et al., 2000).
As an admixture (constant infusion method), amino-
phylline (1-2 mg/mL) with ceftazidime was incompatible 
in both 0.9% NaCl and 5% dextrose (25 oC) (Pleasants et 
al., 1992), compatible with cimetidine HCl in 5% dextrose 
for 48 hours (25 oC) (Baptista, Miltrano, 1988) and com-
patible with fluconazole in 0.9% NaCl and 5% dextrose 
for 3 h (25 oC) (Jonhson et al., 1993).
An admixture of furosemide and aminophylline 
in parenteral solutions increases the diuretic effect of 
furosemide in cardiac patients, compared with the use 
of furosemide alone. A binding study showed that small 
doses of aminophylline administered to patients, after uti-
lization of furosemide, can increase the diuretic effect of 
furosemide in children with cardiac pathology (Mclaughin 
et al., 2000).
Furosemide is listed as an essential drug and ami-
nophylline as a supplementary drug by the World Health 
Organization (WHO, 2009). Although newer drugs are 
available, furosemide and aminophylline are routinely 
prescribed in both developing (Mendis et al., 2007) and 
developed countries (Kaufman et al., 2002) due to their 
low cost and efficacy. The clinical importance of furo-
semide is evidenced by the large number of analytical 
procedures available to detect the presence of this drug in 
pharmaceutical and physiological sample.
Since the inherent chemical stability of a drug mole-
cule largely determines the stability of the final pharmaceu-
tical product, regulatory authorities require novel chemical 
entities (NCE) to undergo extensive chemical stability 
evaluation (stress testing) in accordance with the interna-
tionally accepted guidelines of the International Conference 
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on Harmonization (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use.
Therefore, the evaluation of drug stability in paren-
teral solutions, individually or associated, is necessary 
to guarantee therapeutic effectiveness with minimum 
adverse effects, ensuring the patient’s safety and adequate 
treatment. In this sense, the evaluation of furosemide and 
aminophylline as an admixture is urged due to its current 
application in routine clinical practice as an intravenous 
injection.
The purpose of this work was to evaluate possible 
interactions between the drugs and parenteral components, 
and to assess drug stability over 20 h at room temperature. 
The 20 h duration was selected because this period was 
determined to be the maximum storage time from mixing 
to administration in Brazilian clinical practice. Furosemide 
and aminophylline were added to parenteral solutions of 
20% mannitol and 0.9% NaCl, and their behavior studied 
individually and as an admixture using a spectrophotome-
ter and HPLC as per the methods proposed by Ruiz-Angel 
(Ruiz-Angel et al., 2006).
MATERIAL AND METHODS
Glassware and equipment
All glassware was immersed in a 50% ethanol so-
lution of 1 M NaOH for 24 h, drained and transferred to a 
solution of 1 M nitric acid for 6 h, rinsed for 24 h in puri-
fied water (Milli-Q) and autoclaved for 30 min at 121°C.
The pH of all solutions was measured with a pHme-
ter (Accumet AR20, Fisher Scientific, USA) and absorban-
ce was measured using a spectrophotometer (Beckman 
DU-640, USA) and 1 cm quartz cuvettes. For all assays, 
samples were assessed at 25 oC.
Solutions preparation
A 4 mg/mL stock solution of furosemide (FSM; Me-
dley S/A Indústria Farmacêutica, São Paulo State, Brazil) 
was made by dissolving into a solution of 32.5 mM NaOH 
in water for injection (WFI) with a final pH of 9.5±0.5. A 
24 mg/mL stock solution of aminophylline (APN;  Medley 
S/A Indústria Farmacêutica, São Paulo State, Brazil) was 
made in WFI to yield a stock solution with a final pH of 
9.5±0.5. Stock solutions were prepared with all solvents at 
room temperature (25 oC) immediately prior to use.
An aliquot of the drug stock solutions was added 
individually or combined to either 250 mL of WFI or 
250 mL of commercially available parenteral solutions 
(PS) of either 20% mannitol or 0.9% NaCl (Aster Phar-
maceutics Labs, Ltd., São Paulo State, Brazil) to a final 
concentration of 1.6 mg/mL for FSM and 0.96 mg/mL 
for APN; solutions in WFI were used to generate cali-
bration curves. The solutions were prepared and stored 
in glass beakers covered with plastic wrap in triplicate, 
as follows: (i) 80% parenteral solution with 16% FSM 
stock solution and 4% WFI (solvent for APN), (ii) 80% 
parenteral solution with 4% APN stock solution and 
16% WFI+NaOH (pH 9-10, solvent for FSM), (iii) 80% 
parenteral solution with 16% FSM and 4% APN stock 
solutions. Samples were assayed at pH 6.5-7.5 (pH ob-
tained after successive dilutions with parenteral solutions 
without adjustment) or pH 10-11 using a solution of 
32.5 mM NaOH to minimize further dilution of the drug, 
mannitol or salt concentrations.
The mixing ratios and storage conditions emulated 
routine conditions in the hospital setting. Assaying at pH 
6.5-7.5 was done to emulate final drug/parenteral solutions 
for patient use. In aqueous solution, FSM and APN are 
most stable at pH 10-11; adjustment of the pH to 10-11 
was done to compare the solutions of these drugs at the 
pH with optimal stability.
Immediately after mixing and after 20 h storage at 
25 oC, protected from light, the pH and absorbance of these 
solutions were measured at 25 °C. The absorbance was 
measured at 228 and 275 nm for FSM and APN, respecti-
vely, and also at both wavelengths for solutions containing 
the drugs combined (Santos et al., 2007).
HPLC
Reversed-phase HPLC was performed on a Shima-
dzu LC 10 with photodiode detector (PDA SPD-M10A; 
software LC solution; Shimadzu, Japan) using a 250 x 
4.6 mm (i.d.) column pre-packed with C18 (Shim-pack 
VP–ODS, Shimadzu, Japan) with 0.6 mL/min flow at 
25 oC and a sample injection volume of 20 µL; the mobile 
phase consisted of 30 % acetonitrile and 70% phospha-
te buffer (pH 7.0) and eluted samples were detected at 
228 nm and 275 nm.
Oxidation
Immediately after mixing, triplicate 3 mL aliquots 
of each drug/PS solution at pH 10-11 were exposed to a 
strong oxidant, drug/PS solution:10% H2O2 (2:1, v/v), to 
promote drug degradation and to evaluate if the degra-
dation products could interfere with the sample analysis 
by HPLC. After 1 h oxidation with H2O2, triplicate 20 μL 
samples in solution of 20% mannitol were analyzed by 
HPLC and compared to untreated samples. No residual 
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H2O2 was detected after 1 h contact with the drug/PS 
solutions (30).
RESULTS AND DISCUSSION
Absorbance Scans
Standard solutions of FSM and APN in WFI, and in 
parenteral solutions (PS) of 0.9% NaCl and 20% mannitol 
(pH 7.0±0.5), were used to generate the calibration curves. 
The absorbance calibration curves for FSM (λ = 228 nm) 
using commercial (Hypofarma Instituto de Hypodermia 
e Farmácia S/A., Brazil) and standard drug (Medley S/A 
Indústria Farmacêutica, São Paulo, Brazil) ranged from 
2 - 10 μg/mL. The calibration curve for APN (λ = 275 nm; 
purity >99%, Medley S/A Indústria Farmacêutica, São 
Paulo, Brazil) ranged from 2.4 -19.2 μg/mL. The equations 
derived from the commercial drug curves were used for 
calculating drug concentrations; the calibration results 
using the commercial drugs were selected to relate this 
assay to compounds used in the clinical setting.
Furosemide Stability
Furosemide in 20% mannitol (pH 10-11) showed 
higher absorbance values after 20 h (initial concentra-
tion 1.6 mg/mL versus 2.47 mg/mL after 20 h) with this 
difference attributed to changes in furosemide molecular 
structure in the presence of mannitol. Upon immediate 
mixing, FSM in 0.9% NaCl (pH 10-11) showed a decrease 
in concentration to 1.47 mg/mL compared to initial con-
centration (1.60 mg/mL). After 20 h, the concentrations of 
FSM were closer to initial values (1.52 mg/mL) showing 
that FSM was stable in 0.9% NaCl parenteral solutions 
for up to 20 h.
FSM stability in 20% mannitol solution at pH 10-11, 
as measured by absorbance after a period of 20 h, showed 
a standard deviation higher than 5% (p>5%) and therefore 
the obtained data was not conclusive.
FSM in 20% mannitol (pH 6.5-7.5) showed initial 
concentrations of 2.46 mg/mL, an increase compared to 
the amount added to the solution (1.60 mg/mL). After 
20 h concentrations remained high at 2.44 mg/mL. Initial 
absorbance readings of FSM in 0.9% NaCl (pH 6.5-7.5), 
showed concentrations of 1.80 mg/mL dropping after 20 h 
to 1.38 mg/mL.
Aminophylline stability
Initial concentrations of APN in 20% mannitol 
(pH 10-11) were measured at 1.01 mg/mL, values that 
were closer to the calculated 0.96 mg/mL at initial mixing. 
After 20 h, APN concentrations in these solutions decrea-
sed to 0.80 mg/mL. In solutions of 0.9% NaCl (pH 10-11), 
initial APN concentrations were 0.96 mg/mL whereas 
after 20 h the APN concentrations dropped to 0.93 mg/
mL. These results showed that APN was stable in both 
parenteral solutions at pH 10-11.
In solutions of 20% mannitol (pH 6.5-7.5), APN 
showed initial concentrations of 0.9 mg/mL compared 
with 0.85 mg/mL after 20 h. APN in 0.9% NaCl (pH 6.5-
7.5) showed initial concentrations of 0.99 mg/mL whereas 
after 20 h the concentration was 0.92 mg/mL. These results 
show that APN is stable in both solutions at neutral pH.
Stability of furosemide and aminophylline 
admixtures
At a pH of 10-11, APN in the presence of FSM, in 
both 0.9% NaCl and 20% mannitol solutions, showed an 
increase in initial concentrations and also after 20 h. This 
increase could be attributed to the contribution of a minor 
absorbance of FSM at the same wavelength used to detect 
APN (l = 275 nm), hampering an accurate determination 
of APN stability in the presence of FSM using a spectro-
photometer. Therefore, FSM stability was examined in 
samples containing FSM and APN combined in either 
the mannitol or NaCl solutions (both at pH 10-11) and 
analyzed after initial preparation and after 20 h storage by 
HPLC. Although peak retention times for APN were con-
sistent either alone or combined with FSM, as an admix-
ture, APN stability could not be verified by concentration 
using HPLC. This was because FSM contributed to the 
absorbance values in the wavelength used to detect APN, 
consistently yielding higher concentrations for APN than 
the calculated amount. The results were compared to the 
absorbance readings of the standards and for the individual 
drugs immediately after preparation and after 20 h.
Immediately after mixing of FSM and APN in 20% 
mannitol solutions (pH 10-11) observed concentrations 
were 99 μg/mL for APN and 170 μg/mL for FSM, higher 
than the calculated addition of 96 μg/mL (APN) and 160 
μg/mL (FSM), but within limits of experimental error 
(<10%). As an admixture of FSM and APN in 20% man-
nitol solutions (pH 10-11), FSM initial stability and after 
20 h was similar to FSM alone in 20% mannitol. Combined 
with APN, similar results were observed for FSM in 0.9% 
NaCl solutions (pH 10-11) to those seen with the drug 
alone in this solution.
Ghanekar et al. (1978) examined the stability of 
FSM in different solutions at various concentrations of 
sugar and observed that increasing absorbance values 
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correlated with changes in pH as the sugar concentrations 
increased. These results could be related to the increase in 
absorbance for FSM in mannitol in the pH 10-11 and pH 
6.5-7.5 ranges observed in this study. Christensen (1983) 
studied the stability of FSM in oral liquid drug products 
and also reported a loss in stability in acidic medium and 
sucrose solutions.
HPLC elution profiles
In this study, the HPLC methodology was valida-
ted in accordance with the guidelines contained in the 
International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use – ICH, 2005 (33). The parameters evaluated 
were specificity, linearity, range, precision, and accuracy 
of the methodology, and determination of stress testing 
using an oxidant.
Validation of the HPLC analyses were proven by 
determining if FSM and APN can be detected consistently 
by comparing the elution profiles of the samples with the 
standard reference solutions of FSM and APN in water for 
injection (WFI). The retention times for sample solutions 
and the standards were compared and evaluated (Figures 
1, 2, and 3).
Precision was evaluated by testing seven repetitive 
samplings with 100% of the standard drug concentrations 
(FSM 160 μg/mL and APN 96 μg/mL; Table 1); linearity 
was determined by testing drug concentrations ranging 
from 75 to 150% of standard concentration. Variance, 
standard deviation and coefficient of variance were also 
evaluated.
Samples of drugs, alone or combined, in 20% manni-
tol (pH 10-11) were exposed to a strong oxidant (H2O2) and 
the elution profiles then compared to untreated samples 
using HPLC (Figures 1-4). For oxidized APN, the elution 
profiles showed two peaks, but only one corresponded 
to APN (4.5 min, peak 2), exhibiting the same retention 
time as untreated APN solutions. The minor peak was not 
identified. Oxidized FSM solutions showed changes in 
retention time (9.4 min) compared to untreated FSM so-
lutions (8.4 min). This indicated that after 20 h storage in 
20% mannitol, FSM was stable, but significantly modified 
upon exposure to an oxidant.
With both APN and FSM added to 20% manni-
tol (pH 10-11), two peaks were obtained, the first peak 
corresponding to APN (retention time 4.5 min) and the 
second peak corresponding to FSM (retention time 8.5 
min). In the oxidized samples, the elution profile showed 
four peaks with retention times unrelated to the untreated 
samples (Figure 4).
FIGURE 1 - HPLC chromatogram of furosemide (8.5 min) and 
aminophylline (4.5 min) combined in 20% mannitol (pH 10-11) 
upon preparation at 25 oC. 
FIGURE 2 - HPLC chromatogram of aminophylline in 20% 
mannitol solution (pH 10-11) upon preparation at 25 oC.
FIGURE 3 - HPLC chromatogram of furosemide in 20% 
mannitol solution (pH 10-11) upon preparation at 25 oC.
FIGURE 4 - HPLC chromatogram and spectra of eluted samples 
from FSM and APN combined in 20% mannitol (pH 10-11) after 
oxidation with H2O2.
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Individually, peak retention times and concentra-
tions (peak height) for FSM and APN by HPLC were 
constant after 20 h showing that both drugs are compatible 
in 20% mannitol (pH 10-11) parenteral solutions. Com-
bined, HPLC showed neither significant changes in the 
elution profiles nor the presence of other peaks, suggesting 
that both drugs are compatible as an admixture in 20% 
mannitol (pH 10-11).
Baptista et al. (1988), studied the stability of an 
admixture of APN and cimetidine HCl in 0.5% glucose 
parenteral solutions (D5W) by HPLC. Their samples were 
analyzed after 1, 6, 24 and 48 h with no significant pH 
changes observed in either the test or control solutions. 
The study showed that cimetidine HCl (1200 mg) and 
APN (500 mg) when admixed in 1 L of D5W are both 
chemically stable and physically compatible for 48 h at 
room temperature.
Paul et al.(1983), studied the stability of APN in 
three parenteral solutions using HPLC and confirmed it 
was stable in alkaline media with an optimal pH 8.6-9.0. 
Aminophylline concentrations lower than 40 mg/mL 
appear to be stable over a wide pH range (Baptista et al., 
1988). Admixtures of aminophylline and amino acid so-
lutions added directly to large volume parenteral nutritive 
solutions in concentrations not exceeding 1.5 mg/mL are 
stable for 24 h (Ciszewska-Jedraski et al., 1995).
CONCLUSIONS
Individually, FSM and APN added to 20% mannitol 
and 0.9% NaCl solutions had the highest stability at pH 10-11. 
When FSM and APN were combined in the same parenteral 
solutions, the behavior of FSM was similar to the behavior 
observed for the drug individually in the same solutions.
TABLE I - Precision, standard deviation, variance and %CV of HPLC retention times (minutes) for solutions of furosemide 
(λ = 228 nm) and aminophylline (λ = 275 nm) in 20% mannitol solutions after 20 h at 25°C, individually and combined
Retention times of FSM and APN admixture.
Replicate No.
Retention
Times
RSD Reference 
Std Dev
Maximum, Minimum,
Mean, Median
Std Dev Variance %CV
FSM 
 228 nm
20% Man
pH 10-11
1st
2nd
3rd
4th
5th
6th
7th
8.486
8.442
8.438
8.405
8.402
8.377
8.372
0.040
8.486
8.372
8.417
8.405
0.0375 0014 0.4449
APN
275 nm 
20% Man
pH 10-11
1st
2nd
3rd
4th
5th
6th
7th
4.526
4.529
4.537
4.529
4.530
4.531
4.539
0.0047
4.539
4.526
4.532
4.530
0.0043 0.00002 0.0957 
Retention times of FSM and APN individually in solution. 
Replicate No. Retention Times RSD
Maximum, Minimum,
Mean, Median
Std Dev Variance %CV
FSM
228 nm
20% Man
pH 10-11
1st
2nd
3rd
4th
8.293
8.274
8.272
8.303
0.015
8.303
8.272
8.286
8.284
0.0130 0.0002 0.1570 
APN
275 nm 
20% Man
pH 10-11
1st
2nd
3rd
4th
4.414
4.417
4.416
4.409
0.004
4.417
4.409
4.414
4.415
0.0031 0.00001 0.0698 
* RSD-Reference standard deviation refers to deviation obtained in analytical data and in this case was the same as Std Deviation, 
and therefore a single data value was considered.
Stability of furosemide and aminophylline in parenteral solutions 95
With the solutions at neutral pH, the stability of FSM 
could not be verified because the concentrations of FSM 
were higher than the calculated initial concentration. As 
an admixture with FSM, the stability of APN in parenteral 
solutions of 20% mannitol and 0.9% NaCl could not be ve-
rified because the absorbance of FSM at 275 nm interfered 
with the detection of APN. Although absorbance measu-
rements are useful for detecting molecular decomposition 
(blue shift) or the formation of soluble aggregates (red shift 
or peak broadening), this study clearly reveals that the use 
of a spectrophotometer was inadequate for FSM at neutral 
pH and for FSM and APN combined.
 Future studies will be conducted assessing APN 
stability in 20% mannitol and 0.9% NaCl solutions, using 
revised HPLC methods to further utilize the only method 
enabling detection of APN in the presence of FSM.
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